The role of phenofibrate in the treatment of microvascular complications of type 2 diabetes mellitus
Results of numerous studies give definitive evidence that phenofibrate affects activity of PPAR-a receptors in liver and thereby decreases the level oflipids responsible for the development of atherosclerosis (VLDL, small dense LDL); simultaneously, it increases the level of anti-atherogenic HDL.Act...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | EN RU |
| Publié: |
Endocrinology Research Centre
2009
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/28b800a6fc9641ab9b439ccb4e17d1c4 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| Résumé: | Results of numerous studies give definitive evidence that phenofibrate affects activity of PPAR-a receptors in liver and thereby decreases the level oflipids responsible for the development of atherosclerosis (VLDL, small dense LDL); simultaneously, it increases the level of anti-atherogenic HDL.Activation of PPAR-a receptors in vascular cells decreases activity of inflammation markers, such as C-reactive protein, TNF-a, IL-6, fibrinogen,etc. These effects of phenofibrate eventually lead to reduced risk of macro- and microvascular diabetic complications. |
|---|